AERES Biomedical and Lpath Therapeutics Sign Agreement to Humanize Sphingomab™ Antibody

London, UK, 12th September, 2005 – AERES Biomedical, Ltd. (London, UK) announced today that it has signed an agreement with Lpath Therapeutics Inc. (San Diego, USA) to humanize its Sphingomab™ antibody. Lpath will provide the murine antibody to AERES, which will use its proprietary humanization technology to provide a humanized Sphingomab™ clinical candidate. Financial terms […]

Continue Reading